Bowitz Lothe IM, Kleive D, Pomianowska E, Cvancarova M, Kure E, Dueland S, Gladhaug IP, Labori KJ(2019) Clinical relevance of pancreatobiliary and intestinal subtypes of ampullary and duodenal adenocarcinoma: Pattern of recurrence, chemotherapy, and survival after pancreatoduodenectomy Pancreatology, 19(2), 316-324 DOI 10.1016/j.pan.2019.01.019, PubMed 30713128
Jansen YJL, Rozeman EA, Mason R, Goldinger SM, Geukes Foppen MH, Hoejbergs L, Schmidt H, van Thienen JV, Haanen JBAG, Tiainen L, Svane IM, Mäkelä S, Seremet T, Arance A, Dummer R, Bastholt L, Nyakas M, Straume O, Menzies AM, Long GV, Atkinson V, Blank CU, Neyns B(2019) Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma Ann Oncol(in press) DOI 10.1093/annonc/mdz110, PubMed 30923820
Nyakas M, Aamdal E, Jacobsen KD, Guren TK, Aamdal S, Hagene KT, Brunsvig P, Yndestad A, Halvorsen B, Tasken KA, Aukrust P, Maelandsmo GM, Ueland T(2019) Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma Clin Exp Immunol(in press) DOI 10.1111/cei.13283, PubMed 30821848
